Sage Therapeutics (NASDAQ:SAGE) phase 2 trial for ET treatment disappoints
Full story: https://grafa.com/news/sage-therapeutics--nasdaq-sage--phase-2-trial-for-et-treatment-disappoints-250846
Sage Therapeutics (NASDAQ:SAGE) in collaboration with Biogen (NASDAQ:BIIB), today announced that their Phase 2 KINETIC 2 study evaluating SAGE-324 (BIIB124) as a potential treatment for essential tremor (ET) has not met its primary endpoint.
The study results revealed no statistically significant dose-response relationship or differences between any dose of SAGE-324 and placebo in terms of changes from baseline to Day 91 on the TETRAS Performance Subscale.
Dr. Laura Gault, MD, PhD, Chief Medical Officer at Sage Therapeutics, expressed disappointment in the study's outcomes, stating, “We are disappointed that the results do not support further development of SAGE-324 in ET.”
This sentiment underscores the challenges in addressing this complex neurological condition.
Given these results, Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development of SAGE-324 in this indication.
The companies are currently evaluating next steps, if any, for exploring other potential indications for SAGE-324.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
